Quantcast

Latest Athersys Inc. Stories

2011-02-10 20:44:10

Results show how adult stem cell therapy reduces inflammatory damage Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem®, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke. The study, conducted by leading...

2011-01-24 11:41:00

CLEVELAND, Jan. 24, 2011 /PRNewswire/ -- Athersys, Inc. (Nasdaq: ATHX), a clinical stage biopharmaceutical company, today announced that its January 11th Retail Investor Conferences.com presentation is available for on-demand viewing. Gil Van Bokkelen, PhD, Chairman and Chief Executive Officer of Athersys, presented to retail investors through the virtual investor conference platform. To view the archived presentation, click on www.retailinvestorconferences.com. The Company's...

2011-01-19 14:43:39

Results illustrate potential value of Athersys' adult stem cell therapy to reduce damage and promote neuronal regrowth Case Western Reserve University School of Medicine and Athersys, Inc. (NASDAQ: ATHX) announced a joint scientific study on spinal cord injury will be published today in the January issue of the Journal of Neuroscience. The study, by leading researchers from the Department of Neurosciences at the School of Medicine and scientists at Athersys, presents data supporting the...

2011-01-07 15:17:00

CLEVELAND, Jan. 7, 2011 /PRNewswire/ -- Athersys, Inc. (Nasdaq: ATHX) today announced that its CEO, Dr. Gil Van Bokkelen Ph.D., will present at Retail Investor Confrences.com. DATE: January 11, 2011 TIME: 10:00 AM EST LINK: www.retailinvestorconferences.com This will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." If...

2010-07-28 15:23:00

VANCOUVER, July 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) announced positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, which represent at least four months of post-treatment patient data, demonstrate that...

5229b84c9492b56ac1ccae691c6495711
2009-12-21 12:55:00

Athersys, Inc. announced today that it has entered into an agreement with Pfizer Inc. to develop and commercialize MultiStem for the treatment of Inflammatory Bowel Disease ("IBD"). MultiStem is an investigational stem cell therapy currently in development by Athersys for several other conditions, including acute myocardial infarction, bone marrow transplant support, and ischemic stroke. Under the terms of the agreement, Athersys will receive an up-front cash payment of $6 million from...

2009-06-25 08:11:00

Funding supports multiple commercial, emerging and pilot projects CLEVELAND, June 25 /PRNewswire-USNewswire/ -- The Center for Stem Cell & Regenerative Medicine (CSCRM), comprised of Case Western Reserve University (CWRU), Cleveland Clinic (CC), University Hospitals (UH), and Athersys, Inc. has received $5 million from Ohio's Third Frontier Commission under the Research Commercialization Program. The funding will help support new and innovative stem cell technologies including two...

2008-11-12 12:00:31

CLEVELAND, Nov. 12, 2008 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced the achievement of another clinical development milestone related to its discovery alliance with Bristol-Myers Squibb Company (NYSE:BMY). Bristol-Myers Squibb notified the Company that it has initiated a phase II trial for a small molecule discovered using a target provided by Athersys, thereby triggering a milestone payment. Athersys has collaborated with Bristol-Myers Squibb since 2001, applying its...

2008-11-10 18:00:22

CLEVELAND, Ohio, Nov. 10, 2008 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its results for the quarter ended September 30, 2008 and provided an update on key clinical development programs, including ATHX-105 and MultiStem. In the third quarter, the Company filed an Investigational New Drug (IND) application for a Phase II clinical trial of ATHX-105. The FDA provided comments and requests for additional information and placed the study on partial clinical hold. In...

2008-10-14 09:00:45

CLEVELAND, Oct. 14, 2008 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced the presentation of data from its ongoing phase I clinical trial of MultiStem(r) for individuals following acute myocardial infarction (AMI). Marc Penn, M.D., Ph.D., Director of the Bakken Heart-Brain Institute at the Cleveland Clinic and co-principal investigator of the study, presented summary data yesterday at the annual Transvascular Cardiovascular Therapeutics conference (TCT) in Washington, D.C....


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related